Ellipses Pharma features in the Guardian Innovations In Oncology supplement By leveraging a cloud-based platform, our SAG members provide invaluable scientific and clinical insights, validate asset selection, and offer unbiased input during the drug development process using real-world evidence. This collaborative effort ensures better decision-making, faster development, and increased chances of success in bringing potential [...]

Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]

Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]

Ellipses Pharma featured in Nature Research Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D. Read the full article here. 

EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]